2Seventy Bio Inc
NASDAQ:TSVT
2Seventy Bio Inc
Gross Profit
2Seventy Bio Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
2Seventy Bio Inc
NASDAQ:TSVT
|
Gross Profit
$19.9m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$39.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$22.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$20.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$9.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$12.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
2Seventy Bio Inc
Glance View
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.
See Also
What is 2Seventy Bio Inc's Gross Profit?
Gross Profit
19.9m
USD
Based on the financial report for Dec 31, 2024, 2Seventy Bio Inc's Gross Profit amounts to 19.9m USD.
What is 2Seventy Bio Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
-14%
Over the last year, the Gross Profit growth was -76%. The average annual Gross Profit growth rates for 2Seventy Bio Inc have been -27% over the past three years , -14% over the past five years .
You don't have any saved screeners yet